Authors:
Monali Tayade, Shishanka Wangnoo
Download free PDF
Tele-epilepsy Market Size & Share 2026-2035
Report ID: GMI11022
|
Published Date: August 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Tele-epilepsy Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Tele-Epilepsy Market Size
The tele-epilepsy market was valued at USD 571.3 million in 2025 and is projected to reach USD 2.3 billion by 2035, advancing at a 14.9% CAGR over 2026–2035. The 2026 market value is USD 650.5 million.
Tele-epilepsy Market Key Takeaways
Market Leader: Medtronic plc led with over 13% market share in 2025.
Leading Players: Top 5 players in this market include Medtronic plc, NeuroPace, Inc., Ceribell, Inc., Empatica Inc., BioSerenity SAS, which collectively held a market share of 46% in 2025.
The addressable market includes software for seizure analytics and clinical decision support, tele-consultation and monitoring services, tele-education, and hardware such as ambulatory EEG recorders and wearable seizure-detection devices. It excludes conventional epilepsy care delivered without a remote clinical, monitoring, or connected-device component.
The estimate applies a bottom-up triangulation of component revenues, recurring service contracts, and connected monitoring hardware, checked against institutional adoption and regional telehealth infrastructure. Historic coverage spans 2022–2024, with 2025 as the base year and 2026–2035 as the forecast period. Growth rests on the shift from episodic EEG encounters to continuous management workflows: wearables capture longitudinal signals, cloud platforms organize those signals, and specialist services convert them into care decisions. Epilepsy affects about 50 million people worldwide, and approximately 80% of affected people live in low- and middle-income countries, where specialist access remains constrained. World Health Organization, 2025 [1]World Health Organization, “Epilepsy” - who.int
GMI Analyst View
Tele-epilepsy is moving from a peripheral telehealth use case toward a care-delivery layer for patients requiring ongoing seizure characterization. The 14.9% forecast reflects not simply device adoption, but the ability to reuse the same remote data stream across consultation, medication review, and escalation decisions. The commercial advantage will shift toward platforms that combine signal capture, clinical interpretation, and workflow integration through 2030. Hardware-only offerings remain relevant, but their retention economics depend on connection to a reimbursable monitoring or specialist-service pathway.
Key Drivers
Rising prevalence expands the care burden while neurological specialist capacity remains uneven. Remote services make scarce specialist review available beyond tertiary epilepsy centers, particularly for monitoring that would otherwise require travel or admission. The patient-access mechanism is reinforced by the global distribution of epilepsy burden. World Health Organization, 2025
Demand for remote monitoring is also a capacity-management response. Wearable EEG data and remote review extend clinician reach, while reimbursement treatment for remote physiological monitoring and chronic care management creates an institutional purchasing rationale in the United States. Centers for Medicare & Medicaid Services, 2025 [2]Centers for Medicare & Medicaid Services, “Telehealth” - cms.gov The operational benefit is fewer avoidable in-person touchpoints; the commercial implication is recurring service revenue rather than a single diagnostic-device sale.
AI-enabled signal classification improves the clinical value of remote data. Deep-learning approaches for EEG classification have reported sensitivity above 90% in recent clinical validation literature. IEEE, 2025 [3]IEEE, “EEG Signal Classification Research” - ieee.org The relevant market effect is not algorithm novelty by itself. Higher alert specificity reduces review burden, allowing providers to manage a larger monitored population without proportionate neurologist staffing.
Patient and caregiver education supports adoption where continuous monitoring addresses uncertainty around unobserved seizures, medication response, and nocturnal events. The American Epilepsy Society has promoted remote-monitoring integration for patients with poorly controlled generalized epilepsy. American Epilepsy Society, 2025 [4]American Epilepsy Society, “Epilepsy Resources” - aesnet.org Pediatric demand is especially tied to caregiver oversight and long treatment horizons.
Key Restraints
Continuous transmission and cloud storage of neurological data require encryption, access controls, audit processes, and data-residency governance. HIPAA requirements in the United States and GDPR obligations in the European Union raise implementation complexity for connected monitoring platforms. European Commission, 2025 [5]European Commission, “Digital Health and Medical Devices” - ec.europa.eu Federated-learning architectures may reduce centralization of patient data, but they do not remove the need for clinical governance and cybersecurity investment.
Reimbursement remains a structural constraint because payment treatment for teleconsultation, remote EEG interpretation, and AI-supported analytics differs across payers and geographies. CMS coverage expansion provides a route to adoption, but it does not establish equivalent reimbursement across all care activities or payer categories. Centers for Medicare & Medicaid Services, 2025 This distinction favors vendors that can demonstrate a clear billing pathway and documented clinical workflow value.
GMI Analyst View
The driver-restraint balance remains favorable through 2030 because the specialist-access problem is more durable than the current reimbursement and integration barriers. Privacy, interoperability, and reimbursement requirements will lengthen sales cycles rather than prevent adoption. Platforms that enter with a clinically validated device but lack service and payer integration will face weaker renewal economics. The next competitive threshold will be proof that remote monitoring changes care delivery at an acceptable cost, not merely proof that a device can transmit data.
Tele-Epilepsy Market Segment Analysis
By Component
Software includes cloud-based and on-premises analytics, patient dashboards, and clinical decision support. Cloud-based software is favored for scalable access and interoperability; Seer Medical’s cloud-hosted ambulatory monitoring workflow illustrates the model. On-premises software remains necessary where data-residency rules or institutional security requirements limit external hosting. The software category’s 30% share reflects a shift from raw EEG acquisition toward data organization and actionability.
Services are the largest component at 50.3% of 2025 revenue. Tele-consultation connects patients and referring facilities to epilepsy specialists; Real Time Tele-Epilepsy Consultants addresses hospitals without on-site epileptologist coverage. Tele-monitoring and screening uses ambulatory EEG and clinical review, with CortiCare providing a managed-service model. Tele-education and training applies structured frameworks from the International League Against Epilepsy to patients, caregivers, and nonspecialist providers. International League Against Epilepsy, 2025 [6]International League Against Epilepsy, “Epilepsy Education Frameworks” - ilae.org Other services include remote device management, analytics reporting, compliance support, and patient engagement.
Hardware accounts for 19.7% of 2025 revenue and includes wearable EEG headsets, ambulatory EEG recorders, and seizure-detection wristbands. Empatica’s Embrace2, Epitel’s EPOD, and Nihon Kohden ambulatory EEG systems serve consumer, clinical, and ambulatory applications. Device pricing faces scale and miniaturization pressure, but clinically validated hardware retains value when linked to AI analytics or ongoing specialist review.
By Epilepsy Type
Focal seizure applications lead with 50.5% share. Focal seizures arise from a localized cortical area and often require extended monitoring to characterize onset and medication response. NeuroPace’s RNS System combines responsive neurostimulation with continuous electrocorticographic recording, making remote review central to therapy optimization.
Generalized seizures account for 34% of 2025 revenue. Wearables that combine accelerometry and electrodermal activity support detection of convulsive events outside clinical settings. Empatica’s Embrace2 is positioned in generalized tonic-clonic monitoring, while automated detection is increasingly incorporated into remote programs for poorly controlled generalized epilepsy. American Epilepsy Society, 2025
Combined seizure cases represent 15.5% of the market. These patients require multi-modal recording and more intensive clinical oversight because focal and generalized patterns coexist. Multi-class AI classification will determine how far remote platforms can extend into this technically demanding segment through 2035.
By Age Group
Pediatrics represents 40.2% of 2025 revenue. Continuous monitoring has particular value where caregivers need visibility into nocturnal events and early seizure characterization. LivaNova’s VNS Therapy System links remote parameter monitoring to pediatric and adult epilepsy care. NIH-supported evidence recognizes the role of continuous monitoring in documenting events missed in standard clinical encounters. National Institutes of Health, 2025 [7]National Institutes of Health, “Neurological Disorders Research” - nih.gov
Adults lead at 59.8% share. Remote management addresses medication adherence, driving-related assessment, workplace considerations, and self-managed care. Approximately 3.4 million adults in the United States live with active epilepsy. Centers for Disease Control and Prevention, 2025 [8]Centers for Disease Control and Prevention, “Epilepsy” - cdc.gov The adult category supports demand for discreet wearable monitoring and shared seizure-diary, medication-tracking, and outcome-reporting workflows.
By End Use
Healthcare providers hold 62.6% of market revenue. Hospitals and clinics use integrated systems such as Philips Healthcare neurology monitoring solutions to extend EEG capacity beyond inpatient labs. Specialized epilepsy centers use tele-monitoring, AI analytics, and teleconsultation for presurgical evaluation support and post-discharge follow-up. Homecare settings use clinically supervised monitoring programs; Ovation Healthcare illustrates a managed model combining remote EEG, care coordination, and teleconsultation.
Patients account for 26.3% of revenue through direct-use devices and service subscriptions. ORCA evidence from Q1 2026 distributor interviews indicated that demand for reimbursement-eligible seizure-detection wearables grew by more than 40% year over year, linked to Medicare Advantage coverage expansion. Other end users account for 11% and include research institutions, academic medical centers, pharmaceutical companies, and government health programs.
GMI Analyst View
Component leadership will remain with services because specialist interpretation and care coordination are the recurring constraints in epilepsy management. The cross-segment effect is material: improved wearable adoption increases the volume of longitudinal data, which in turn raises demand for software interpretation and managed clinical services. Through 2030, the strongest offerings will package hardware, analytics, and specialist review as a single accountable workflow. ORCA’s Q1 2026 channel evidence points to reimbursement eligibility as a practical filter for patient-directed wearable demand.
Tele-Epilepsy Market Regional Analysis
North America
North America holds 42.2% of 2025 revenue. The United States benefits from telehealth reimbursement pathways applicable to remote physiological monitoring and chronic care management. Centers for Medicare & Medicaid Services, 2025 Canada adds demand through provincial telemedicine investment for rural and remote specialist access. The regional constraint is uneven payer reimbursement for remote EEG interpretation and AI analytics.
Europe
Europe accounts for 27.3% of 2025 revenue. Germany, France, the UK, Spain, Italy, and the Netherlands comprise the approved country scope. EU MDR 2017/745 and the European Commission’s digital-health direction shape market access and deployment requirements. European Commission, 2025 Germany’s DiGA pathway offers a reimbursement precedent for qualifying digital health applications, while NHS-linked remote monitoring pilots support the UK opportunity. Data protection and authorization requirements remain the central regional constraint.
Asia Pacific
Asia Pacific holds 22.0% share and is the fastest-growing region. China, Japan, India, Australia, and South Korea define the approved scope. China’s patient population exceeds 9 million, while India has an estimated 10–12 million people with epilepsy and material specialist shortages outside major cities. World Health Organization, 2025 GSMA, 2025 [9]GSMA, “Mobile Connectivity” - gsma.com Nihon Kohden’s EEG portfolio provides regional clinical monitoring presence. South Korea’s 5G infrastructure and digital-health reimbursement programs support wearable and AI-enabled deployment. Infrastructure quality and local regulatory requirements will determine the pace of conversion from need to paid adoption.
Latin America and Middle East & Africa
Latin America covers Brazil, Mexico, and Argentina; Brazil is one of the leading emerging markets by adoption potential. The Middle East & Africa scope includes Saudi Arabia, South Africa, and the UAE. These regions represent part of the remaining 8.6% of global revenue with Latin America. Their growth case rests on telehealth infrastructure investment and the ability to extend specialist access, but reimbursement maturity and connectivity reliability constrain near-term scaling.
GMI Analyst View
Regional divergence reflects care-system design rather than disease burden alone. North America commercializes remote workflows through provider purchasing and reimbursement; Europe balances reimbursement opportunity against compliance complexity; Asia Pacific offers the largest access-driven expansion potential. India, Brazil, and South Korea will remain important adoption markets through 2030 for different reasons: specialist scarcity, developing digital health demand, and advanced connectivity, respectively. Vendors that impose a single operating model across regions will face slower implementation.
Tele-Epilepsy Market Share & Competitive Landscape
The top five companies-Medtronic plc, NeuroPace, Ceribell, Empatica, and BioSerenity SAS collectively accounted for approximately 46% of the market’s revenue in 2025. Medtronic leads at approximately 13%, supported by neuromodulation assets, the CareLink remote monitoring infrastructure, and enterprise hospital relationships. The remaining 54% is dispersed across specialist monitoring providers, regional firms, and broader telehealth operators.
Medtronic competes through implanted-device monitoring, including Percept PC DBS with BrainSense technology. NeuroPace differentiates through the RNS System for medically refractory focal epilepsy. Ceribell addresses acute care with Clarity AI seizure detection. Empatica operates across consumer and clinical wearable channels through Embrace2. BioSerenity combines connected garment-based EEG recording, cloud analytics, and remote review in European deployments.
The broader company set includes CortiCare, Epitel, LivaNova, Nihon Kohden, Ovation Healthcare, Philips Healthcare, Real Time Tele-Epilepsy Consultants, Seer Medical, Teladoc Health, and Vidyo. Their positions span managed outpatient EEG review, simplified wearable EEG, VNS therapy monitoring, clinical EEG acquisition, homecare management, hospital informatics, specialist consultation, ambulatory AI analytics, virtual neurology access, and secure telehealth video infrastructure. Competitive differentiation depends on clinical validation, EHR interoperability, regulatory clearance, and regional service reach.
Recent developments recorded in the approved evidence include Ceribell’s May 2026 partnership expansion across 150 US community hospitals, Empatica’s March 2026 FDA clearance expansion for Embrace2 adult focal seizure monitoring, NeuroPace’s January 2026 publication of 10-year RNS data, Teladoc’s November 2025 neurology virtual-care launch in Canada and the UK, BioSerenity’s September 2025 CE mark registration, Medtronic’s July 2025 BrainSense software update, and Seer Medical’s April 2025 UK expansion.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →